

IHI Call Days | Call 9

● Motion Analysis, Multi-Omics, Novel Biosensors for Osteoarthritis Diagnosis and New Therapeutics: Mani**OA**ba

Contact person name:  Feza Korkusuz MD

Organisation: Hacettepe University

E-mail: feza.korkusuz@hacettepe.edu.tr; feza.korkusuz@gmail.com

Link to the:

- https://ihicalldays2024.converve.io/index.html?page=cat_tech2
- https://ihicalldays2024.converve.io/index.php?page=profiles&action=show¶ms%5Bid%5D=272¶ms%5Bshow%5D=pers¶ms%5Bpers_id%5D=286

Challenges and objectives



- Osteoarthritis (**OA**) is a non-communicable disease defined with morbidity and mortality.
- Diagnosing **OA** early and accurately, along with preventing it and providing suitable treatment, poses significant challenges.
- There is a need to quantify functional loss and metabolic changes in serum and synovial joint fluid (SJF) using advanced technologies such as **motion analysis + multi-omics > biosensors** and generating **> new therapeutics**.

WHO Osteoarthritis Fact


- In 2019, about 528 million people worldwide were living with osteoarthritis, an increase of 113% since 1990.
- About 73% of people living with osteoarthritis are older than 55 years, and 60% are female.
- With a prevalence of 365 million, the knee is the most frequently affected joint, followed by the hip and the hand.
- 344 million people living with osteoarthritis experience severity levels (moderate or severe) that could benefit from rehabilitation.
- With aging populations and increasing rates of obesity and injury, the prevalence of osteoarthritis is expected to continue to increase globally.
- Osteoarthritis is an inevitable consequence of aging.

Your approach to solve the problem

- Motion Analysis (**MAI**) Technology (<https://maimotion.com/>)
- **Multi-Omics** (<https://chondromics.org/>)
- **Biosensors**



Digital Microfluidics (Inflammation)
Surface Plasma Resonance
(Anabolism)



Modified from Mobashari A et al. Osteoarthritis & Cartilage 2017;25:199-208.

- **New Therapeutics**

Is your project suitable for IHI?


- **Multi-layered, Multi-centered** and **Multi-disciplinary** research.
- Where do you see the contribution of industry in your proposal?
 - **Biotechnology industry** or **SME**
 - Upscale our biosensor technology from TRL 4-6 to the market.
 - **Patient societies**
 - Patient-centred and personalized medicinal approach.
 - **Regulatory bodies**

Outcomes

- **Marker-less motion analysis** can be used as a new paradigm for the early and accurate diagnosis of OA. This can be used to longitudinal evaluation of the natural course and response to treatment by regulatory bodies.
- **Multi-omics biosensors** outcomes can lead to the better development of **biosensors** for inflammation and anabolism (from the bench to the bedside)
- **New therapeutics** such as nucleic acid delivery already proven for bone regeneration can be transferred to joint repair.

Impact

- Academic:
 - Article publication in the open research Europe platform.
 - Educating young researchers.
 - New research projects.
- Economic:
 - Patent applications.
- Societal:
 - Web page and social media platforms.
 - Electronic bulletins, newsletters, brochures and handouts.
 - Webinars and seminars.
 - Workshops and surveys.



Knee Joint Articular Cartilage Treatment Algorithm*

1. Non-Surgical

- Exercise
- Weight management
- NSAIDs
- Unloading braces

2. Disease Modifying

- Oral GAG & CS
- IA Hyaluronan
- IA Corticosteroid
- IA Peptide

3. Hydrogel

- Non-degradable polymeric hydrogels

4. Cellular

- PRPs
- Activated PRPs
- Stromal Vascular Fraction
- Mesenchymal Stem Cells
- Extracellular Vesicles

5. Surgical

- Micro- or Nano-Fx.
- Mosaicplasty
- Allografts
- MACI
- High tibial osteotomy
- Subchondral bioplasty
- Partial or total joint replacement surgery

*Modified from the OARSI Guidelines.

Expertise and resources

- We have:



- We are looking for:
 - Industrial partners
 - SMEs
 - Patient Societies
 - Regulatory Bodies

Additional information

